Strategic partnerships Pharmaron Beijing has active and recent collaboration momentum with industry leaders including Eli Lilly and CN Bio, signaling a strong channel for expanded CDMO partnerships and co-development opportunities in radiolabeling, organ-on-a-chip, and gene therapy support.

Global expansion Investments in UK and Europe for mRNA, viral vectors and GMP scale facilities indicate readiness to support international clients requiring cross-border manufacturing, regulatory alignment, and global supply chain capabilities.

Radiolabelled capabilities A broad suite of radiochemistry and isotopically labeled metabolism services, including 14C microtracer AMS, positions Pharmaron as a go-to partner for high-sensitivity pharmacokinetics studies and early drug development.

Diversified portfolio End-to-end capabilities spanning chemistry, biology, DMPK, pharmacology, safety, and clinical development enable one-stop outsourcing for clients seeking integrated R&D solutions and streamlined project management.

Market positioning Active growth through strategic asset acquisition in breeding facilities and partnerships with CN Bio and major pharma players suggests a competitive edge in securing long-term, multiyear contracts in North America, Europe, and Asia.